Just saw that CABA got bumped up to a Zacks Rank #2 (Buy), which is interesting because it's basically their way of saying earnings estimates are trending up. I know Wall Street analysts can be all over the place, but this Zacks system is different - it's purely data-driven based on how analysts are revising their EPS forecasts.

So here's the thing with CABA: over the past three months, the consensus estimate for the company has climbed 1.6%. That might not sound like much, but apparently this kind of revision trend is one of the strongest predictors of near-term stock moves. Institutional investors use these numbers to recalculate what a stock should actually be worth, and when they start buying or selling in bulk, that's what moves the needle.

The upgrade puts CABA in the top 20% of stocks they track for estimate revisions. For fiscal year 2025, they're expecting the company to post -$2.15 per share, but the fact that analysts keep raising their numbers is what matters here. Not saying this is a guaranteed win, but if the earnings picture keeps improving, there could be upside. Worth keeping an eye on if you're looking at biotech plays.